Plus Therapeutics is trying to turn hard-to-treat brain and spinal cancers into a growth story by pairing targeted radiotherapy with its own diagnostic test, backed by grant funding and a leaner cost base. The big question is whether its small set of key programs can clear trials and win insurance coverage before ongoing losses and competition squeeze the business.Read more
Plus Therapeutics aims to bring new cancer treatments and a related diagnostic to market, but long approval timelines and uneven insurance coverage could slow its progress. The bigger question is whether it can keep funding development without repeatedly tapping investors while larger rivals push into the same space.Read more
Key Takeaways Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth. Advancements and strategic partnerships indicate significant market opportunities, enhancing revenue potential and profit margins through reduced costs and expanded markets.Read more
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
